Advances in percutaneous coronary intervention and multidisciplinary risk assessment are necessary to safely treat increasingly higher-risk patients with severe coronary artery disease.
Highlights the need for dedicated interventional cardiology specialists to safely perform PCI in increasingly complex, high-risk patients with severe coronary artery disease.
Patients with severe coronary artery disease with a clinical indication for revascularization but who are at high procedural risk because of patient comorbidities, complexity of coronary anatomy, and/or poor hemodynamics represent an understudied and potentially underserved patient population. Through advances in percutaneous interventional techniques and technologies and improvements in patient selection, current percutaneous coronary intervention may allow appropriate patients to benefit safely from revascularization procedures that might not have been offered in the past. The burgeoning interest in these procedures in some respects reflects an evolutionary step within the field of percutaneous coronary intervention. However, because of the clinical complexity of many of these patients and procedures, it is critical to develop dedicated specialists within interventional cardiology who are trained with the cognitive and technical skills to select these patients appropriately and to perform these procedures safely. Preprocedural issues such as multidisciplinary risk and treatment assessments are highly relevant to the successful treatment of these patients, and knowledge gaps and future directions to improve outcomes in this emerging area are discussed. Ultimately, an evolution of contemporary interventional cardiology is necessary to treat the increasingly higher-risk patients with whom we are confronted.
Kirtane et al. (Mon,) conducted a review in Severe coronary artery disease with high procedural risk. Percutaneous coronary intervention was evaluated. Advances in percutaneous coronary intervention and multidisciplinary risk assessment are necessary to safely treat increasingly higher-risk patients with severe coronary artery disease.